Loading patent…
AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, Tuskegee University, The University of North Carolina at Chapel Hill, The United States Government as represented by the Department of Veterans Affairs
InventorsCecelia C. Yates-Binder, Jesse Jaynes, Monte S. Willis, Richard J. Bodnar, Zariel I. Johnson
Estimating the term…
Interferon-γ-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.
A method of treating or inhibiting the development of fibrosis in a subject, comprising administering to the subject a therapeutically effective amount of a peptide or a composition comprising the peptide, wherein:
A method of treating myocardial infarction, ischemia-reperfusion injury, or a cardiovascular disease in a subject, comprising administering to the subject a therapeutically effective amount of a peptide or a composition comprising the peptide, wherein:
A method of inhibiting CXCR3 signaling in a cell or in a subject, comprising administering to the cell or the subject (i) a synthetic peptide 12 to 30 amino acids in length, wherein the peptide is an antagonist of C-X-C chemokine receptor 3 (CXCR3) signaling, and wherein the synthetic peptide comprises at least 12 consecutive amino acids of any one of SEQ ID NOs:
A method of treating myocarditis in a subject, comprising administering to the subject a therapeutically effective amount of a synthetic peptide 12 to 30 amino acids in length, wherein the peptide is an antagonist of C-X-C chemokine receptor 3 (CXCR3) signaling, and wherein the synthetic peptide comprises at least 12 consecutive amino acids of any one of SEQ ID NOs:
A method of treating atherosclerosis in a subject, comprising administering to the subject a therapeutically effective amount of (i) a synthetic peptide 12 to 30 amino acids in length, wherein the peptide is an antagonist of C-X-C chemokine receptor 3 (CXCR3) signaling, and wherein the synthetic peptide comprises at least 12 consecutive amino acids of any one of SEQ ID NOs:
Dependencies are inferred from the claim text.